Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
IMVT

IMVT - Immunovant Inc Stock Price, Fair Value and News

30.70USD-0.78 (-2.48%)Delayed

Market Summary

IMVT
USD30.70-0.78
Delayed
-2.48%

IMVT Alerts

  • 6 major insider sales recently.

IMVT Stock Price

View Fullscreen

IMVT RSI Chart

IMVT Valuation

Market Cap

4.5B

Price/Earnings (Trailing)

-18.32

EV/EBITDA

-16.84

Price/Free Cashflow

-21.18

MarketCap/EBT

-18.27

IMVT Price/Sales (Trailing)

IMVT Profitability

Return on Equity

-35.84%

Return on Assets

-34.22%

Free Cashflow Yield

-4.72%

IMVT Fundamentals

IMVT Earnings

Earnings (TTM)

-243.4M

Earnings Growth (Yr)

18.68%

Earnings Growth (Qtr)

12.35%

Breaking Down IMVT Revenue

Last 7 days

4.5%

Last 30 days

8.0%

Last 90 days

-17.3%

Trailing 12 Months

44.6%

How does IMVT drawdown profile look like?

IMVT Financial Health

Current Ratio

22.14

IMVT Investor Care

Shares Dilution (1Y)

11.55%

Diluted EPS (TTM)

-1.84

Tracking the Latest Insider Buys and Sells of Immunovant Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 24, 2024
geffner michael
sold
-94,242
28.9
-3,261
chief medical officer
Apr 24, 2024
stout jay s
sold
-209,207
28.9
-7,239
chief technology officer
Apr 24, 2024
levine mark s.
sold
-114,531
28.9
-3,963
chief legal officer
Apr 17, 2024
salzmann peter
sold
-990,269
29.058
-34,079
chief executive officer
Apr 17, 2024
levine mark s.
sold
-285,554
29.0581
-9,827
chief legal officer
Apr 17, 2024
macias william l.
sold
-240,602
29.0582
-8,280
chief medical officer
Apr 17, 2024
barnett eva renee
sold
-356,049
29.0581
-12,253
chief financial officer
Apr 17, 2024
butchko julia g.
sold
-293,923
29.0581
-10,115
chief development officer
Apr 09, 2024
barnett eva renee
sold
-115,023
31.18
-3,689
chief financial officer
Apr 09, 2024
butchko julia g.
sold
-32,832
31.18
-1,053
chief development officer

1–10 of 50

Which funds bought or sold IMVT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
COMERICA BANK
reduced
-21.79
-11,298
16,930
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-89.00
-23,697,900
2,184,320
-%
May 16, 2024
Creekmur Asset Management LLC
added
26.27
-678
20,808
0.01%
May 16, 2024
CASTLEARK MANAGEMENT LLC
new
-
2,599,020
2,599,020
0.11%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.45
-624,111
1,646,480
-%
May 16, 2024
AWM Investment Company, Inc.
unchanged
-
-687,400
2,261,700
0.30%
May 15, 2024
ArrowMark Colorado Holdings LLC
reduced
-4.83
-836,962
2,261,700
0.03%
May 15, 2024
AQR CAPITAL MANAGEMENT LLC
added
28.47
-42,851
2,862,600
-%
May 15, 2024
ACUTA CAPITAL PARTNERS, LLC
reduced
-22.72
-2,050,370
2,983,700
1.94%
May 15, 2024
NOMURA HOLDINGS INC
new
-
830,625
830,625
-%

1–10 of 41

Are Funds Buying or Selling IMVT?

Are funds buying IMVT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IMVT
No. of Funds

Unveiling Immunovant Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
deep track capital, lp
0.69%
1e+06
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G
Oct 04, 2023
roivant sciences ltd.
55.3%
79,815,331
SC 13D/A
Feb 14, 2023
deep track capital, lp
7.52%
9,710,000
SC 13G/A
Dec 05, 2022
rtw investments, lp
0.0%
0
SC 13G/A
Dec 02, 2022
rtw investments, lp
5.87%
7,592,253
SC 13G/A
Feb 11, 2022
deep track capital, lp
5.83%
6,780,827
SC 13G
Aug 02, 2021
roivant sciences ltd.
63.8%
73,398,664
SC 13D/A
Mar 08, 2021
roivant sciences ltd.
57.5%
56,377,388
SC 13D/A
Feb 16, 2021
rtw investments, lp
7.75%
7,592,253
SC 13G/A

Recent SEC filings of Immunovant Inc

View All Filings
Date Filed Form Type Document
Apr 26, 2024
4
Insider Trading
Apr 26, 2024
4
Insider Trading
Apr 26, 2024
4
Insider Trading
Apr 19, 2024
4
Insider Trading
Apr 19, 2024
4
Insider Trading
Apr 19, 2024
4
Insider Trading
Apr 19, 2024
4
Insider Trading
Apr 19, 2024
4
Insider Trading
Apr 15, 2024
S-8
Employee Benefits Plan
Apr 10, 2024
4
Insider Trading

Peers (Alternatives to Immunovant Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
50.9B
6.8B
28.49% 6.05%
-8.53
7.44
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
18.9B
2.0B
2.79% -21.33%
-56.9
9.43
75.20% 68.82%
14.7B
2.5B
-14.30% -15.94%
71.65
5.96
13.74% 186.89%
12.8B
3.8B
8.33% -10.25%
17.2
3.4
8.58% 129.81%
MID-CAP
5.6B
107.9M
20.58% 115.45%
-10.31
48.09
54.84% -28.31%
5.0B
524.1M
-13.99% -52.79%
-12.02
9.57
394.93% 39.61%
3.6B
251.0M
9.96% -0.29%
-12.28
14.5
73.58% -86.73%
3.1B
240.7M
9.94% -31.73%
-6.53
12.77
-1.03% -213.43%
2.4B
813.8M
-14.08% -36.34%
-1.4K
3
56.43% 98.83%
SMALL-CAP
1.9B
411.3M
3.06% 35.16%
29.91
4.73
60.38% -34.49%
1.8B
996.6M
233.93% 75.07%
-4.58
1.83
-26.66% 65.49%
480.9M
881.7K
21.10% 351.81%
-14.25
481.06
-77.61% 33.36%
310.9M
4.9M
8.40% 53.85%
-2.49
63.89
-54.97% 48.23%
17.1M
2.1M
4.76% 108.64%
-0.74
7.61
-13.45% 69.54%

Immunovant Inc News

Latest updates
MarketBeat13 hours ago
Yahoo Finance24 Apr 202407:00 am

Immunovant Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets143.6%71129235140645642845951654356738841243345429010912724.0011714.00-
  Current Assets144.1%71129135040445442645651354056438540942945028610912722.002.0013.000.00
    Cash Equivalents156.0%69127033037743340642749452755937940042244428010112419.004.007.0012.00
  Net PPE23.7%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00-0.00-
Liabilities-20.3%32.0040.0051.0043.0042.0032.0022.0046.0038.0030.0022.0021.0019.0015.0023.0015.0015.0047.004.006.000.00
  Current Liabilities-20.3%32.0040.0051.0043.0041.0032.0021.0045.0036.0028.0021.0019.0016.0013.0020.0015.00-0.000.000.000.00
Shareholder's Equity169.8%67925230036241539643647050553636639141443826894.001125.005.007.008.00
  Retained Earnings-7.4%-750-698-640-566-506-443-395-355-308-266-229-198-170-138-117-91.23-70.67-59.380.00-24.84-448*
  Additional Paid-In Capital50.5%1,43095094092892084183382581380359459058457738618518336.005.0032.000.00
Shares Outstanding10.4%14513113113012911711711610710998.0098.00---------
Float------239---347---1,461---115---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations21.6%-47,098-60,060-47,370-55,793-46,395-20,186-65,819-32,956-31,895-20,047-21,214-22,496-22,815-24,218-13,798-23,050-4,418-301-8,332-450*-7,387
  Share Based Compensation-2.9%10,22010,52910,6887,5468,9068,1577,68711,86310,1598,3613,8615,4885,9923,3613,9811,8401,4143,137572233236
Cashflow From Investing-285.3%-131-34.00-45.00-26.00-98.00-31.00-42.00-118-74.00-44.00-18.00-95.00-29.00-39.00-47.00-10.00-13.00-4.00---
Cashflow From Financing317362.2%469,84414889023370,631-21.00--200,03891.00763446188,350193,553101108,96932,6015,303-17614,496
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

IMVT Income Statement

2023-12-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:    
Research and development$ 48,338$ 42,252$ 146,872$ 108,420
Acquired in-process research and development010,00012,50010,000
General and administrative13,21511,77542,45835,597
Total operating expenses61,55364,027201,830154,017
Interest income(8,933)(2,944)(16,569)(4,098)
Other (income) expense, net(1,094)1,757(1,579)609
Loss before provision (benefit) for income taxes(51,526)(62,840)(183,682)(150,528)
Provision (benefit) for income taxes(108)3873351,000
Net loss$ (51,418)$ (63,227)$ (184,017)$ (151,528)
Net loss per common share - basic (in dollars per share)$ (0.36)$ (0.49)$ (1.36)$ (1.26)
Net loss per common share - diluted (in dollars per share)$ (0.36)$ (0.49)$ (1.36)$ (1.26)
Weighted-average common shares outstanding – basic (in shares)144,523,034128,574,190135,577,267120,665,299
Weighted-average common shares outstanding – diluted (in shares)144,523,034128,574,190135,577,267120,665,299

IMVT Balance Sheet

2023-12-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Mar. 31, 2023
Current assets:  
Cash and cash equivalents$ 690,937$ 376,532
Accounts receivable1,029700
Prepaid expenses and other current assets18,81027,101
Total current assets710,776404,333
Operating lease right-of-use assets2941,172
Property and equipment, net376333
Total assets711,446405,838
Current liabilities:  
Accounts payable3,9101,353
Accrued expenses27,88640,771
Current portion of operating lease liabilities3061,173
Total current liabilities32,10243,297
Operating lease liabilities, net of current portion047
Total liabilities32,10243,344
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 145,094,052 shares issued and outstanding at December 31, 2023 and 500,000,000 shares authorized, 130,329,863 shares issued and outstanding at March 31, 20231413
Additional paid-in capital1,430,294927,976
Accumulated other comprehensive (loss) income(600)852
Accumulated deficit(750,364)(566,347)
Total stockholders’ equity679,344362,494
Total liabilities and stockholders’ equity711,446405,838
Series A  preferred stock  
Stockholders’ equity:  
Preferred stock00
Preferred Stock  
Stockholders’ equity:  
Preferred stock$ 0$ 0
IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
 CEO
 WEBSITEhttps://immunovant.com
 INDUSTRYBiotechnology
 EMPLOYEES164

Immunovant Inc Frequently Asked Questions


What is the ticker symbol for Immunovant Inc? What does IMVT stand for in stocks?

IMVT is the stock ticker symbol of Immunovant Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Immunovant Inc (IMVT)?

As of Fri May 17 2024, market cap of Immunovant Inc is 4.46 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMVT stock?

You can check IMVT's fair value in chart for subscribers.

What is the fair value of IMVT stock?

You can check IMVT's fair value in chart for subscribers. The fair value of Immunovant Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Immunovant Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IMVT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Immunovant Inc a good stock to buy?

The fair value guage provides a quick view whether IMVT is over valued or under valued. Whether Immunovant Inc is cheap or expensive depends on the assumptions which impact Immunovant Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMVT.